![Jürgen Gerlach](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Career history of Jürgen Gerlach
Former positions of Jürgen Gerlach
Companies | Position | Start | End |
---|---|---|---|
DVC Deutsche Venture Capital
![]() DVC Deutsche Venture Capital Investment ManagersFinance DVC Deutsche Venture Capital (DVC) is an independent venture capital firm focused on science-based sectors. DVC was established in 1998 and is based in Munich. The firm operates in partnership with Deutsche Bank AG (FR: DBK; NYSE: DB). | President | 1998-12-31 | 2015-06-29 |
KeyNeurotek Pharmaceuticals AG
![]() KeyNeurotek Pharmaceuticals AG Pharmaceuticals: OtherHealth Technology KeyNeurotek Pharmaceuticals AG is a biopharmaceutical company focused on the development of innovative small molecule drugs for the treatment of neuronal and autoimmune diseases. KeyNeurotek’s drug portfolio covers the entire drug development chain from research stage to advanced clinical development. At present, two compounds are in clinical development, KN38-7271 and KN203, both addressing significant markets such as traumatic brain injury, TBI, stroke, and urinary incontinence/overactive bladder. The company’s product development is based on its proprietary technology platform, which has been specifically tailored to diseases of the central nervous system, TELOMICS. KeyNeurotek was founded by Dr Frank Striggow, Frank Baumgart, Prof Dr Klaus G. Reymann and Prof Dr Henning Scheich in May 2000. The company is located in Magdeburg, Germany. | Director/Board Member | 2009-08-30 | 2011-08-02 |
Avontec GmbH
![]() Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Director/Board Member | 2009-11-04 | 2010-06-15 |
Training of Jürgen Gerlach
Wuerzburg Schweinfurt University of Applied Sciences | Masters Business Admin |
Statistics
International
Germany | 5 |
Operational
Director/Board Member | 2 |
President | 1 |
Masters Business Admin | 1 |
Sectoral
Health Technology | 3 |
Finance | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 3 |
---|---|
DVC Deutsche Venture Capital
![]() DVC Deutsche Venture Capital Investment ManagersFinance DVC Deutsche Venture Capital (DVC) is an independent venture capital firm focused on science-based sectors. DVC was established in 1998 and is based in Munich. The firm operates in partnership with Deutsche Bank AG (FR: DBK; NYSE: DB). | Finance |
KeyNeurotek Pharmaceuticals AG
![]() KeyNeurotek Pharmaceuticals AG Pharmaceuticals: OtherHealth Technology KeyNeurotek Pharmaceuticals AG is a biopharmaceutical company focused on the development of innovative small molecule drugs for the treatment of neuronal and autoimmune diseases. KeyNeurotek’s drug portfolio covers the entire drug development chain from research stage to advanced clinical development. At present, two compounds are in clinical development, KN38-7271 and KN203, both addressing significant markets such as traumatic brain injury, TBI, stroke, and urinary incontinence/overactive bladder. The company’s product development is based on its proprietary technology platform, which has been specifically tailored to diseases of the central nervous system, TELOMICS. KeyNeurotek was founded by Dr Frank Striggow, Frank Baumgart, Prof Dr Klaus G. Reymann and Prof Dr Henning Scheich in May 2000. The company is located in Magdeburg, Germany. | Health Technology |
Avontec GmbH
![]() Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Health Technology |
- Stock Market
- Insiders
- Jürgen Gerlach
- Experience